2. Search Result
Search Result
Results for "

HCCLM3

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Peptides

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0754
    Eupalinolide A

    		YAP HSP Reactive Oxygen Species (ROS) ERK Autophagy Apoptosis Tyrosinase DNA/RNA Synthesis Neurological Disease Inflammation/Immunology Cancer
    Eupalinolide A is a Yes-associated protein (YAP) degrader and HSP70 inducer. Eupalinolide A inhibits osteogenic differentiation of tendon-derived stem cells (TDSCs). Eupalinolide A induces autophagy in hepatocellular carcinoma cells via activating the ROS/ERK signaling pathway. Eupalinolide A protects PAM212 cells from UVB-, Menadione (HY-B0332)-, or heat shock-induced apoptosis. Eupalinolide A alleviates trauma-induced heterotopic ossification (HO) of Achilles tendon and inhibits growth of MHCC97-L and HCCLM3 hepatocellular carcinoma xenograft tumors in mice. Eupalinolide A can be used for the study of traumatic heterotopic ossification of tendons and hepatocellular carcinoma [3].
    Eupalinolide A
  • HY-142684
    Pyruvate Carboxylase-IN-1
    2 Publications Verification

    		 Mitochondrial Metabolism Cancer
    Pyruvate Carboxylase-IN-1 (compound 37) is a potent pyruvate carboxylase inhibitor with antiproliferative activity. The IC50 values ​​of pyruvate carboxylase-IN-1 against PC in cell lysates and cells are 0.204 and 0.104 μM, respectively .
    Pyruvate Carboxylase-IN-1
  • HY-N2232
    N-​Feruloyloctopamine

    N-trans-Feruloyloctopamine

    		 Akt p38 MAPK Apoptosis Cadherin Cancer
    N-Feruloyloctopamine (N-trans-Feruloyloctopamine) is an antioxidant component that can be isolated from garlic skin. N-Feruloyloctopamine can inhibit tumor cell proliferation and invasion, and induce apoptosis. N-Feruloyloctopamine has antitumor activity and can be used in the research of tumors such as hepatocellular carcinoma .
    N-​Feruloyloctopamine
  • HY-N4087
    Platycodin D2
    3 Publications Verification

    		 Mitophagy Autophagy Ferroptosis Interleukin Related IFNAR Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Platycodin D2 is an orally active triterpenoid saponin found in Platycodon grandiflorum. Platycodin D2 induces mitophagy in cancer cells through NIX, thereby activating the P21/CyclinA2 pathway and promoting cell senescence. Platycodin D2 induces mitochondrial dysfunction, enhances autophagy, inhibits hepatocellular carcinoma cell proliferation, and exhibits anti-tumor activity against multiple cancer cell types. Platycodin D2 promotes mRNA expression of T-bet, GATA-3, Th1 cytokines IL-2 and IFN-γ, and Th2 cytokines IL-4 and IL-10, enhances splenocyte proliferation, and acts as a vaccine adjuvant with low rabbit red blood cell hemolytic activity. Platycodin D2 induces mitochondrial ROS production, incomplete autophagy, and ferroptosis to inhibit breast cancer cell proliferation. Platycodin D2 can be used for the research of cancer, inflammation and immunology [3].
    Platycodin D2
  • HY-147918
    Anticancer agent 73

    		DNA/RNA Synthesis Cancer
    Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo .
    Anticancer agent 73
  • HY-P11228
    FPP29

    		PROTACs Apoptosis DNA/RNA Synthesis Cancer
    FPP29 is a potent peptide-based FOXM1 PROTAC degrader. FPP29 induces ubiquitination and degradation of FOXM1. FPP29 inhibits FOXM1 via the ubiquitin-proteasome degradation pathway. FPP29 induces Apoptosis. FPP29 suppresses tumor growth in hepatocellular carcinoma xenograft models. FPP29 can be used in the research of hepatocellular carcinoma (cell-penetrating peptide: (HY-P0133); VHL ligase ligand: (HY-P11493); linker: (HY-W013664); FOXM1 ligand: (HY-P11494)) .
    FPP29
  • HY-147259
    Dalmelitinib

    		c-Met/HGFR Cancer
    Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC50: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .
    Dalmelitinib
  • HY-162650
    SL44

    		ClpP Cancer
    SL44 is an agonist for human caseinolytic protease P (HsClpP), with an EC50 of 1.30 μM. SL44 inhibits the proliferation of LM3 with an IC50 of 3.1 μM. SL44 induces apoptosis in HCC cells, through the degradation of respiratory chain complex subunits. SL44 exhibits antitumor efficacy in mouse models without obvious toxicity (LD50=400 mg/kg). SL44 exhibits good pharmacokinetic characters in rat models .
    SL44
  • HY-177796
    TMLB-C16

    		Apoptosis CDK Caspase PARP Cancer
    TMLB-C16 is a potent and orally active B3GAT3 inhibitor with a KD of 3.962 μM. TMLB-C16 suppresses proliferation and migration, and induces cell cycle arrest and apoptosis in MHCC-97H (IC50 = 6.53 μM) and HCCLM3 cells (IC50 = 6.22 μM). TMLB-C16 inhibits tumor growth in both MHCC-97H and HCCLM3 xenograft tumor mouse models without causing obvious toxicity. TMLB-C16 can be used for hepatocellular carcinoma research .
    TMLB-C16
  • HY-161515
    BRD4/NAMPT-IN-1

    		NAMPT Epigenetic Reader Domain Cancer
    BRD4/NAMPT-IN-1 (Compound A2) shows strong inhibitory effects on NAMPT and BRD4 (IC50=35 nM (NAMPT) and 58 nM (BRD4)). BRD4/NAMPT-IN-1 inhibits the growth and migration of hepatocellular carcinoma cells and promotes apoptosis. BRD4/NAMPT-IN-1 also shows potent anticancer effects in HCCLM3 xenograft mouse model, with no obvious toxic effects .
    BRD4/NAMPT-IN-1
  • HY-169239
    MAGL-IN-20

    		MAGL Cancer
    MAGL-IN-20 (compound ±34) is a reversible monoacylglycerol lipase (MAGL) inhibitor. MAGL-IN-20 exhibits appreciable antiproliferative activities against several cancer cells, including H460, HT29, CT-26, Huh7 and HCCLM-3. .
    MAGL-IN-20
  • HY-172885
    TRBP-IN-1

    		DNA/RNA Synthesis MicroRNA Apoptosis Pyroptosis Cancer
    TRBP-IN-1 (Compound 13j) is an orally active TAR RNA binding protein 2 (TRBP) inhibitor (IC50: 12.72 μM). TRBP-IN-1 has significant anti-hepatocellular carcinoma (HCC) activity and can inhibit the proliferation and metastasis of HCC cells (HCCLM3 cells (IC50: 18.96 μM); SK-Hep-1 cells (IC50: 16.45 μM)). TRBP-IN-1 regulates miRNA biogenesis and inhibits oncogenic miRNA expression by targeting TRBP. TRBP-IN-1 induces apoptosis and pyroptosis in HCC cells by inhibiting the level of miRNA. TRBP-IN-1 can be used for targeted therapy research of HCC .
    TRBP-IN-1
  • HY-179033
    Nur77 antagonist 2

    		Nuclear Hormone Receptor 4A/NR4A Apoptosis ASK1 JNK p38 MAPK Cancer
    Nur77 antagonist 2 (Compound 12b) is an orally active Nur77 antagonist with a KD value of 0.42 μM. Nur77 antagonist 2 exhibits proliferative activity on liver cancer cells. Nur77 antagonist 2 stabilizes Nur77 by inhibiting its ubiquitin-proteasomal degradation, leading to Nur77-dependent apoptosis via the ASK1-JNK/p38 pathway. Nur77 antagonist 2 inhibits tumor growth in the HCCLM3 xenograft model. Nur77 antagonist 2 can be used for the study of hepatocellular carcinoma (HCC) .
    Nur77 antagonist 2
  • HY-N1762
    3α,22β-Dihydroxyolean-12-en-29-oic acid

    		Fungal Cancer
    3α,22β-Dihydroxyolean-12-en-29-oic acid is a terpenoid that can be isolated from Maytenus royleanus cufodontis .
    3α,22β-Dihydroxyolean-12-en-29-oic acid
  • HY-180281
    PLAGL2-IN-1

    		Zinc Finger Protein Apoptosis PI3K Akt Cancer
    PLAGL2-IN-1 is a inhibitor of pleiomorphic adenoma-like protein 2 (PLAGL2) with a Kd of 2.23 µM. PLAGL2-IN-1 suppresses PLAGL2 transcriptional activity, induces G0/G1 cell cycle arrest, and apoptosis, thereby inhibiting hepatocellular carcinoma (HCC) cell proliferation. PLAGL2-IN-1 disrupts extracellular matrix organization and suppresses the PI3K-AKT pathway by reducing AKT phosphorylation. PLAGL2-IN-1 inhibits tumor growth in an HCCLM3 xenograft mouse model. PLAGL2-IN-1 can be used for the research of HCC .
    PLAGL2-IN-1
  • HY-152169
    BIHC

    		Interleukin Related Apoptosis TNF Receptor IFNAR NF-κB Bcl-2 Family Inflammation/Immunology
    BIHC is a TNF blocker with anti-inflammatory activity. BIHC can significantly inhibit the proliferation of hepatocellular carcinoma (HCC) cells and exhibits potent cytotoxicity against the HepG2 cell line, capable of inducing cell apoptosis , while demonstrating relatively low toxicity towards normal hepatocytes. Additionally, BIHC can be used for research on inflammatory bowel disease (IBD) .
    BIHC
  • HY-176908
    SIOC-XJC-SF02

    		Drug Derivative Apoptosis Cancer
    SIOC-XJC-SF02 is a Fenofibrate (HY-17356) derivative. SIOC-XJC-SF02 induces Apoptosis. SIOC-XJC-SF02 exhibits significant anti-cancer activity against hepatocellular carcinoma .
    SIOC-XJC-SF02

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: